Visualize HL7 Example and Test Instances (vi7eti), pronounced /viːˈsɛtiː/
Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not intended to be used as a source of information on on healthcare or medicines. The web pages are not kept up to date and are for demonstration purposes only. For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines or the package leaflet of your medicine. For up-to-date information on other healthcare topics, please consult the relevant reliable sources or an healthcare expert, such as a physician etc.
BACK TO LIST

Laboratory Report

Patient
Name: Hayward, Tom
DOB: 07-APR-1975 (Age: 50)
Gender: male
Address:
391 Dean locks
M1 Manchester (United Kingdom)
ID: 3376-612163-7 (ECI)
Report
Date: 13-MAY-2019
Laboratory
dr Ample, Ex
Laboratoire Central Européenne
Boulevard du Jardin Botanique 32
1000 Brussels (Belgium)
Requested by
Cornbrook Medical Practice
City Road 204
M3 3 Manchester (United Kingdom)
Specimen
Collected: 13-MAY-2019

Hematology

Test 13-MAY-2019 Reference Range Unit
Leukocytes [#/volume] in Blood by Automated count 5.7 4.0 - 11.0 10*3/uL
Erythrocytes [#/volume] in Blood by Automated count 4.4 4.2 - 5.6 10*6/uL
Hemoglobin [Mass/volume] in Blood 16.7 13.5 - 17.5 g/dL
Hematocrit [Volume Fraction] of Blood by Automated count 46.4 37 - 49 %
MCV [Entitic mean volume] in Red Blood Cells by Automated count 81.1 80 - 100 fL
MCH [Entitic mass] by Automated count 28.1 27 - 33 pg
MCHC [Entitic Mass/volume] in Red Blood Cells by Automated count 34.6 32 - 36 g/dL
Erythrocyte [DistWidth] in Blood by Automated count 13.5 11.5 - 16.5 %
Platelets [#/volume] in Blood by Automated count 369.8 150 - 450 10*3/uL

Chemistry

Test 13-MAY-2019 Reference Range Unit
Glucose [Mass/volume] in Serum or Plasma 97.4 70 - 100 mg/dL
Urea nitrogen [Mass/volume] in Serum or Plasma 7.1 7 - 20 mg/dL
Creatinine [Mass/volume] in Serum or Plasma 2.7 H 0.6 - 1.2 mg/dL
Calcium [Mass/volume] in Serum or Plasma 10.1 8.5 - 10.5 mg/dL
Sodium [Moles/volume] in Serum or Plasma 139.6 135 - 145 mmol/L
Potassium [Moles/volume] in Serum or Plasma 5.2 H 3.5 - 5.1 mmol/L
Chloride [Moles/volume] in Serum or Plasma 110.1 H 98 - 107 mmol/L
Carbon dioxide, total [Moles/volume] in Serum or Plasma 23.3 22 - 32 mmol/L
Protein [Mass/volume] in Serum or Plasma 6.7 6.0 - 8.3 g/dL
Albumin [Mass/volume] in Serum or Plasma 4.8 3.5 - 5.5 g/dL
Bilirubin.total [Mass/volume] in Serum or Plasma 9.0 H 0.3 - 1.2 mg/dL
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 82.2 39 - 117 U/L
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 39.8 10 - 40 U/L
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 33.4 10 - 40 U/L
Magnesium [Mass/volume] in Serum or Plasma 2.0 1.7 - 2.3 mg/dL
Phosphate [Mass/volume] in Serum or Plasma 3.5 2.5 - 4.5 mg/dL
pH of Arterial blood 7.2 L 7.35 - 7.45 [pH]
Carbon dioxide [Partial pressure] in Arterial blood 39.9 35 - 45 mm[Hg]
Oxygen [Partial pressure] in Arterial blood 83.2 75 - 100 mm[Hg]
Bicarbonate [Moles/volume] in Arterial blood 23.3 22 - 28 mmol/L
Oxygen saturation in Arterial blood 91.0 L 95.0 - 100.0 %
Cholesterol [Mass/volume] in Serum or Plasma 205.4 H 125 - 200 mg/dL
Triglyceride [Mass/volume] in Serum or Plasma 107.3 0 - 150 mg/dL
Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay 123.9 H 0 - 100 mg/dL
Cholesterol in HDL [Mass/volume] in Serum or Plasma 60.0 40 - 60 mg/dL

Coagulation

Test 13-MAY-2019 Reference Range Unit
Prothrombin time (PT) 10.8 9.4 - 12.5 s
INR in Platelet poor plasma by Coagulation assay 1.1 0.9 - 1.1 {INR}
aPTT in Blood by Coagulation assay 29.9 25 - 35 s

Annotation

Conclusion and Recommendations based on this report and previous findings known to us
The patient shows significant renal dysfunction (elevated creatinine), hyperbilirubinemia, mild hyperkalemia, hyperchloremia, metabolic acidosis (low pH, low O2 saturation), and dyslipidemia (high total and LDL cholesterol). Liver enzymes are within normal limits. Hematology and coagulation parameters are unremarkable. Findings suggest possible acute or chronic kidney disease with secondary metabolic disturbances; further nephrological and hepatological evaluation is recommended.